Találati lista | Tudóstér

001-es BibID:	BIBFORM028329
Első szerző:	Eckhardt Sándor
Cím:	Phase II clinical evaluation of etoposide (VP-16-213, Vepesid) as a second-line treatment in ovarian cancer : results of the South-East European Oncology Group (SEEOG) Study / S. Eckhardt, Z. Hernádi, L. Thurzó, A. Telekes, B. Sopkova, Z. Mechl, M. Pawlicki, S. Kerpel-Fronius
Dátum:	1990
ISSN:	0030-2414
Megjegyzések:	The objective of this trial was to define the antitumor activity and toxicity of etoposide for second-line treatment of patients with bulky ovarian carcinoma. Between February 1, 1986 and November 1, 1988 we recruited 82 patients. Out of them 77 (93.9%) were evaluable for toxicity and 71 (86.6%) for response. Patient characteristics are as follows: median age 57 years (range 15-75), median performance status: WHO 1, prior chemotherapy with more than 3 drugs 24 patients, with previous cisplatin 63 patients, with previous adriamycin 47 patients, with previous irradiation plus chemotherapy 17 patients. The following treatment schedule was applied: each patient started with 150 mg/m2 of etoposide administered i.v. on days 1-3. If this first cycle was well tolerated the dosage was escalated to 200 mg/m2 days 1-3. This higher dosage was then repeated at 4-week intervals. For evaluation of response the WHO criteria were used. One patient (1.4%) achieved complete remission and 5 (7.0%) partial remission. In 48 patients (67.6%) minor response or stabilisation of the disease were observed. Seventeen patients (24%) showed no response. The median duration of remission was 5.5 months (range 2-20). The median duration of stabilisation was 3 months (range 2-24). The median survival time was 10 months with a range of 2-30 months. The myelotoxic side-effects are as follows: WBC less than 2,000 was recorded in 6 patients and greater than 1,000 in 2 patients. Thrombocytopaenia with platelet count less than 50,000 occurred in 1 patient. 26 patients had anaemia WHO grades 2 and 3. Non-haematological toxicity consisted of nausea and vomiting (WHO grade 2:20 patients and grade 3:2 patients), alopecia (WHO grades 2-3:14 and 24 patients, respectively). Though the remission rate in this trial was low, the 10-month median survival with an acceptable quality of life can be taken as a fairly good salvage therapy result.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban Petefészekrák
Megjelenés:	Oncology. - 47 : 4 (1990), p. 289-295. -
További szerzők:	Hernádi Zoltán (1948-) (szülész-nőgyógyász, klinikai onkológus) Thurzó László Telekes A. Sopkova, Bozen Mechl, Zdenek Pawlicki, Marek Kerpel-Fronius Sándor
Internet cím:	Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon:

001-es BibID:	BIBFORM028323
Első szerző:	Eckhardt Sándor
Cím:	Activity of Epirubicin in Combination Chemotherapy of Advanced Ovarian Cancer / S. Eckhardt, J. Szántó, O. Cerar, V. Chylak, Z. Hernádi, I. Hindy, S. József, É. Juhos, K. Kolaric, J. Kopecny, I. Koza, Z. Mechl, K. Miksics, L. Németh, M. Pawlicki, S. Plesnicar, E. Ploch, Z. Schoket, Z. Stepanek, L. Svancarová, Z. Vizhányó, B. Zuchovska
Dátum:	1987
ISSN:	0030-2414
Megjegyzések:	The therapeutic efficacy of the combination of cyclophosphamide + epirubicin + cisplatin was evaluated in 107 previously treated or untreated patients with advanced ovarian cancer. The overall response rate was 58.8%, complete remission 36.4% (mean duration-7.62 months) and partial remission 22.4% (mean duration-6.74 months). The response was rated in function of age, menopausal status, performance status and previous therapy. Toxicity (in case of 109 patients) was evaluated according to the WHO recommendation. The similar therapeutic effectiveness and less toxicity of the above drug combination compared to CAP regimen is demonstrated.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban petefészekrák
Megjelenés:	Oncology. - 44 : 2 (1987), p. 69-72. -
További szerzők:	Szántó János (1949-) (onkológus szakorvos) Cerar, O. Chylak, V. Hernádi Zoltán (1948-) (szülész-nőgyógyász, klinikai onkológus) Hindy Iván József Sándor Juhos Éva (onkológus) Kolaric K. Kopecny, J. Koza I. Mechl, Z. Miksics K. Németh L. Pawlicki, Marek Plesnicar, S. Ploch, E. Schoket, Z. Stepanek, Z. Svancarová, L. Vizhányó, Z. Zuchovska, B.
Internet cím:	Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon: